Kiromic Biopharma Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Kiromic Biopharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Kiromic Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Kiromic Biopharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 25.4 M |
Kiromic |
Kiromic Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Kiromic Biopharma on December 17, 2024 and sell it today you would earn a total of 100.00 from holding Kiromic Biopharma or generate -100.0% return on investment over 90 days. Kiromic Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Kiromic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kiromic Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kiromic Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Kiromic Biopharma, and traders can use it to determine the average amount a Kiromic Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KRBP |
Based on monthly moving average Kiromic Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiromic Biopharma by adding Kiromic Biopharma to a well-diversified portfolio.
Kiromic Biopharma Fundamentals Growth
Kiromic OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Kiromic Biopharma, and Kiromic Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kiromic OTC Stock performance.
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 | ||||
| Current Valuation | 9.55 M | ||||
| Shares Outstanding | 1.18 M | ||||
| Price To Book | 15.11 X | ||||
| EBITDA | (29.44 M) | ||||
| Cash And Equivalents | 6.51 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 9.41 M | ||||
| Debt To Equity | 0.20 % | ||||
| Book Value Per Share | (5.35) X | ||||
| Cash Flow From Operations | (23.75 M) | ||||
| Earnings Per Share | (39.68) X | ||||
| Total Asset | 11.97 M | ||||
| Retained Earnings | (101.95 M) | ||||
Things to note about Kiromic Biopharma performance evaluation
Checking the ongoing alerts about Kiromic Biopharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Kiromic Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kiromic Biopharma is not yet fully synchronised with the market data | |
| Kiromic Biopharma has some characteristics of a very speculative penny stock | |
| Kiromic Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (34.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kiromic Biopharma currently holds about 6.51 M in cash with (23.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 68.0% of the company shares are owned by institutional investors |
- Analyzing Kiromic Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kiromic Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Kiromic Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kiromic Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kiromic Biopharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Kiromic Biopharma's otc stock. These opinions can provide insight into Kiromic Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Kiromic Biopharma information on this page should be used as a complementary analysis to other Kiromic Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Kiromic OTC Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |